Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of September 2021. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of August 31, 2021, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Capital Structure Details
- Issued Share Capital (as of August 31, 2021): 5,386,937,397 Ordinary Shares of 25 pence each.
- Treasury Shares: 355,205,950 Ordinary Shares.
- Total Voting Rights: 5,031,731,447.
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period. The document focuses solely on the current state of share capital and voting rights.
Guidance, Outlook, and Risks
The filing text does not provide clear values or statements regarding guidance, outlook, management commentary, risks, contingencies, or unusual items. The primary purpose of this filing is to establish the denominator for shareholder notification calculations under FCA rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,031,731,447) to determine if notification thresholds under FCA rules have been met.
- Confirm the number of shares held in Treasury (355,205,950) which are excluded from voting rights.
- Note that this filing does not contain operational or financial performance results for the period.